Search Results: AbbVie v. Boehringer Ingelheim (adalimumab)

AbbVie Answers BI's Counterclaims in Adalimumab Litigation

As we previously reported, on August 2, 2017, AbbVie filed a complaint against Boehringer Ingelheim (BI) in the U.S. District Court for the District of Delaware regarding BI’s aBLA for a biosimilar version of AbbVie’s Humira® (adalimumab) product.  We also reported last month that BI answered AbbVie’s complaint, and included counterclaims against AbbVie for invalidity…

Read More